Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers
Clinical trial NCT04710407 · COMPLETED
Trial details
- NCT number
- NCT04710407
- Sponsor
- Spero Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-07
- Primary completion
- 2021-03-10
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.